当前位置： SCI文献检索 > VACCINE期刊下所有文献 > The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu.

The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu.

Abstract：

:The aims of this project were: (1) to determine the extent to which infant hepatitis B immunisation is preventing chronic hepatitis B infection in children living in a sample of Pacific Island countries; and (2) to identify factors associated with the successful prevention of hepatitis B infection in these populations. A regional hepatitis B immunisation project which supplied hepatitis B vaccine to 10 Pacific Island countries began in 1995. Seroepidemiological surveys were conducted in Fiji, Kiribati, Tonga and Vanuatu in early 1998. These included immunised pre-school children and their biological mothers, and a historical control group of unimmunised students. Prevalence rates for hepatitis B surface antigen (HBsAg) in the populations of students, mothers and their pre-school children were respectively: Fiji: 6.9, 6.6, 0.7%; Kiribati: 27.4, 15.1, 3.8%; Tonga: 11.1, 18.6, 3.8%; Vanuatu: 16.3, 12.3, 3.0%; and for all four countries: 13.2, 12.5, 2.6%. Compared to the historical control group of students, the pre-school population had a much lower probability of HBsAg positivity (relative risk [RR]=0.19 [95%CI: 0.12-0.31]). Statistically significant differences in risk were apparent for all the countries: Fiji: RR=0.10; Kiribati: RR=0.14; Tonga: RR=0.34; Vanuatu: RR=0.19. This is equivalent to an overall program effectiveness of 81% (95%CI: 69-88%) in reducing chronic carriage. Also, the overall protective effectiveness against vertical hepatitis B transmission resulting in HBsAg positivity among children exposed to HBeAg positive and negative carrier mothers, was estimated to be 70%. By age 6 months, when all children should have had three vaccine doses, completed immunisation rates ranged from 22 (Fiji) to 84% (Vanuatu). Coverage of the first dose being given within 2 days of birth varied from 43% in Kiribati to 92% in Tonga. In conclusion hepatitis B immunisation of infants in these four countries is having a substantial beneficial effect in preventing chronic hepatitis B infection. Nevertheless, there is significant scope for further improving the timeliness of immunisation.

journal_name

Vaccine

journal_title

Vaccine

authors

Wilson N,Ruff TA,Rana BJ,Leydon J,Locarnini S

doi

10.1016/s0264-410x(00)00080-3

subject

Has Abstract

pub_date

2000-07-01 00:00:00

pages

3059-66

issue

26

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(00)00080-3

journal_volume

18

pub_type

杂志文章

相关文献

VACCINE文献大全
  • DNA immunisation against the CFA/I fimbriae of enterotoxigenic Escherichia coli (ETEC).

    abstract：:The CFA/I fimbria promotes the attachment of enterotoxigenic Escherichia coli (ETEC) to the surface of human enterocytes. The generation of a protective immune response requires the induction of antibodies able to block the CFA/I-mediated binding of ETEC to receptors located on the small intestine epithelium or on the...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(00)00244-9

    authors： Alves AM,Lásaro MO,Almeida DF,Ferreira LC

    更新日期：2000-11-22 00:00:00

  • Is there a causal link between hepatitis B vaccination and multiple sclerosis?

    abstract：:After the publication of case reports of hepatitis B vaccinees with onset or relapse of multiple sclerosis (MS), followed by a media-driven scare campaign in France, the perception that hepatitis B vaccine causes MS has developed. This has led to a fall in the acceptance of hepatitis B vaccination particularly in Fren...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(99)00533-2

    authors： Monteyne P,André FE

    更新日期：2000-04-03 00:00:00

  • Novel use of a N2-specific enzyme-linked immunosorbent assay for differentiation of infected from vaccinated animals (DIVA)-based identification of avian influenza.

    abstract：:Proper vaccination with validated companion differentiation of infected from vaccinated animals (DIVA) tests using a vaccine containing a heterologous neuraminidase to the field virus can be effective to control avian influenza (AI). However, indirect immunofluorescent assay, the only field validated DIVA test, has li...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.03.065

    authors： Kwon JS,Kim MC,Jeong OM,Kang HM,Song CS,Kwon JH,Lee YJ

    更新日期：2009-05-21 00:00:00

  • A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.

    abstract：:This study aimed to evaluate the durability of the immunogenicity of MVA85A beyond infancy. Participants in an immunogenicity study of MVA85A administered at age of 4 months had additional evaluation 14 months after initial vaccination for IFN-γ ELISPOT responses to Ag85A peptide and ESAT6/CFP-10 and tuberculin skin t...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2012.06.054

    authors： Odutola AA,Owolabi OA,Owiafe PK,McShane H,Ota MO

    更新日期：2012-08-17 00:00:00

  • Murine response to DNA encoding herpes simplex virus type-1 glycoprotein D targeted to the liver.

    abstract：:Plasmid DNA encoding herpes simplex virus type-1 glycoprotein D (gD-1) was complexed with asialoorosomucoid conjugated to poly-L-lysine. Following its intravenous injection into BALB/c mice, this complex was targeted to the liver. Liver cells expressing gD-1 were detected immunohistochemically through day 6 post-immun...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(99)00438-7

    authors： Rogers JV,Hull BE,Fink PS,Chiou HC,Bigley NJ

    更新日期：2000-02-14 00:00:00

  • A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response.

    abstract：:A strategy to improve the immunogenicity of candidate vaccines is to trigger the innate immune system. Triggering of CD40 at the surface of dendritic cells (DC) is essential in the induction of an efficient immune response. Although CD40 agonist antibodies have been shown to be potent inducers of immune responses in e...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.05.028

    authors： Miconnet I,Pantaleo G

    更新日期：2008-07-29 00:00:00

  • A method for evaluating and comparing immunisation schedules that cover multiple diseases: Illustrative application to the UK routine childhood vaccine schedule.

    abstract：BACKGROUND:In the UK, the childhood immunisation programme is given in the first 5 years of life and protects against 12 vaccine-preventable diseases. Recently, this programme has undergone changes with addition of vaccination against Meningitis B from September 2015 and the removal of the primary dose of protection ag...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.05.083

    authors： Panovska-Griffiths J,Crowe S,Pagel C,Shiri T,Grove P,Utley M

    更新日期：2018-08-23 00:00:00

  • First year allopathic medical student attitudes about vaccination and vaccine hesitancy.

    abstract：:First year medical students at an allopathic medical school regional campus were asked to complete a 10-question survey at both the beginning and the conclusion of a required course on immunology, hematology and oncology. The survey was designed to solicit student attitudes about vaccination and the students' level of...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.10.094

    authors： Onello E,Friedrichsen S,Krafts K,Simmons G Jr,Diebel K

    更新日期：2020-01-22 00:00:00

  • Towards improved process efficiency in vaccine innovation: The Vaccine Innovation Cycle as a validated, conceptual stage-gate model.

    abstract：:Continuing investments in vaccine innovation are insufficiently translated into market entries of novel vaccines. This innovation paradox is in part caused by stakeholders lacking complete understanding of the complex array of steps necessary for vaccine development and collaboration difficulties between the wide vari...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.10.061

    authors： Van de Burgwal LHM,Ribeiro CDS,Van der Waal MB,Claassen E

    更新日期：2018-11-26 00:00:00

  • Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development.

    abstract：:The paramyxoviruses respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) are the two most common agents of severe lower respiratory tract disease in infants and children throughout the world. RSV causes yearly epidemics of bronchiolitis and pneumonia in infants and young children, while PIV3 is a co...

    journal_title：Vaccine

    pub_type：

    doi：10.1016/0264-410x(95)98266-d

    authors： Crowe JE Jr

    更新日期：1995-03-01 00:00:00

  • Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.

    abstract：OBJECTIVE:Pneumococcal disease is a significant problem in immunocompromised persons, particularly in HIV-infected individuals. The CDC recently updated pneumococcal vaccination recommendations for immunocompromised adults, adding the 13-valent pneumococcal conjugate vaccine (PCV13) to the previously recommended 23-val...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.06.037

    authors： Smith KJ,Nowalk MP,Raymund M,Zimmerman RK

    更新日期：2013-08-20 00:00:00

  • Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs.

    abstract：:After introduction of a mono-component vaccine, containing only pertussis toxoid (PT), the incidence of pertussis was significantly higher in the Gothenburg area among children during the period October 1, 1997 until end of 2006 compared to the Rest of Sweden where a vaccine containing PT and two other pertussis antig...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.02.070

    authors： Advani A,Gustafsson L,Ahrén C,Mooi FR,Hallander HO

    更新日期：2011-04-18 00:00:00

  • Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine.

    abstract：:Ten adult volunteers, with low prevaccination levels of serum IgG antibodies against meningococcal antigens (< 1 microg ml(-1)), received three doses of the Norwegian group B meningococcal outer membrane vesicle (OMV) vaccine intramuscularly at weeks 0, 6 and 46. Anti-OMV IgG subclass responses were measured and compa...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)00259-x

    authors： Naess LM,Aarvak T,Aase A,Oftung F,Høiby EA,Sandin R,Michaelsen TE

    更新日期：1999-02-26 00:00:00

  • Researching routine immunization-do we know what we don't know?

    abstract：BACKGROUND:The Expanded Programme on Immunization (EPI), launched in 1974, has developed and implemented a range of strategies and practices over the last three decades to ensure that children and adults receive the vaccines they need to help protect them against vaccine-preventable diseases. Many of these strategies h...

    journal_title：Vaccine

    pub_type：

    doi：10.1016/j.vaccine.2011.08.048

    authors： Clements CJ,Watkins M,de Quadros C,Biellik R,Hadler J,McFarland D,Steinglass R,Luman E,Hennessey K,Dietz V

    更新日期：2011-11-03 00:00:00

  • Eimeria species parasites as novel vaccine delivery vectors: anti-Campylobacter jejuni protective immunity induced by Eimeria tenella-delivered CjaA.

    abstract：:Vaccination of poultry against coccidiosis caused by the Eimeria species is almost entirely based upon varied formulations of live parasites. The recent development of a series of protocols that support genetic complementation by transfection in Eimeria now provides an opportunity to utilise live anticoccidial vaccine...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.02.002

    authors： Clark JD,Oakes RD,Redhead K,Crouch CF,Francis MJ,Tomley FM,Blake DP

    更新日期：2012-03-30 00:00:00

  • Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein.

    abstract：:Recombinant plasmid DNA constructs expressing truncated or full-length dengue-1 envelope (E) with or without the pre-membrane (prM) were tested for immunogenicity in mice, as candidate dengue DNA vaccines. Two plasmids, one expressing the N-terminal 80% E and the other expressing prM and full length E were immunogenic...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(99)00570-8

    authors： Raviprakash K,Kochel TJ,Ewing D,Simmons M,Phillips I,Hayes CG,Porter KR

    更新日期：2000-05-08 00:00:00

  • Potential T cell epitopes within swine-origin triple reassortant influenza A (H3N2) variant virus which emerged in 2011: an immunoinformatics study.

    abstract：:An immuno-informatics study was conducted to determine possible pre-existing T cellular immunity to the recently emerged swine-origin triple reassortant H3N2 variant (S-OtrH3N2v-2011) which acquired the matrix gene of influenza A (H1N1)pdm09. Given the genetic origin of S-OtrH3N2v-2011, our study focused on the hemagg...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.07.054

    authors： Duvvuri VR,Marchand-Austin A,Eshaghi A,Patel SN,Low DE,Gubbay JB

    更新日期：2012-09-14 00:00:00

  • Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques.

    abstract：:The ability of ALVAC- or fowlpox-based simian immunodeficiency virus (SIV) vaccines to boost SIV-specific CD4+ and CD8+ T-cell responses was tested in 10 vaccinia-experienced macaques infected with SIVmac251. The CD8+ T-cell response to the dominant Gag(181-189) CM9 was quantitated in seven Mamu-A*01-positive macaques...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2003.08.028

    authors： Nacsa J,Radaelli A,Edghill-Smith Y,Venzon D,Tsai WP,Morghen Cde G,Panicali D,Tartaglia J,Franchini G

    更新日期：2004-01-26 00:00:00

  • Amount of maternal rotavirus-specific antibodies influence the outcome of rotavirus vaccination of newborn mice with virus-like particles.

    abstract：:In presence of low or high levels of rotavirus-specific maternal antibodies, the ability of newborn mice to respond to immunization with rotavirus RF 8*-2/6/7 VLPs, was evaluated. After parenteral vaccination, 100% of offspring born to low-antibody-titer dams developed rotavirus-specific IgG antibodies (n=7). In contr...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.11.089

    authors： Johansson E,Istrate C,Charpilienne A,Cohen J,Hinkula J,Poncet D,Svensson L,Johansen K

    更新日期：2008-02-06 00:00:00

  • Infants with low vaccine antibody responses have altered innate cytokine response.

    abstract：:We recently identified a population of 10% of infants who respond with sub-protective antibody levels to most routine primary pediatric vaccinations due to altered innate and adaptive immune responses. We term these infants as low vaccine responders (LVRs). Here we report new data showing that TLR7/8 agonist - R848 st...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.09.050

    authors： Surendran N,Nicolosi T,Pichichero M

    更新日期：2016-11-11 00:00:00

  • Laboratory and field evaluation of Schistosoma japonicum DNA vaccines in sheep and water buffalo in China.

    abstract：:Vaccines are needed to control zoonotic Schistosoma japonicum infection and several vaccine candidates have now been identified. Two of these (Sj28GST and Sj23) have shown particular promise in sheep when injected with Freund's adjuvants. The objective of the present work was to find a vaccine formulation which may ha...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(01)00340-1

    authors： Shi F,Zhang Y,Ye P,Lin J,Cai Y,Shen W,Bickle QD,Taylor MG

    更新日期：2001-11-12 00:00:00

  • CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes.

    abstract：:Understanding the requirements for protection against pneumococcal carriage and pneumonia will greatly benefit efforts in controlling these diseases. Several antigens, in addition to the polysaccharide capsule, have been implicated in both the virulence and protective immunity against Streptococcus pneumoniae; one of ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.12.020

    authors： Singh R,Singh S,Briles DE,Taub DD,Hollingshead SK,Lillard JW Jr

    更新日期：2012-02-01 00:00:00

  • Immunopathological responses and kinetics of Brucella melitensis Rev 1 infection after subcutaneous or conjunctival vaccination in rams.

    abstract：:The innocuousness of the Brucella melitensis Rev 1 live attenuated vaccine strain has never been fully assessed in rams. The immunopathological responses and the kinetics and distribution of the infection induced by this strain were determined after subcutaneous or conjunctival vaccination in both young (3-4 months ol...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.03.030

    authors： Muñoz PM,de Miguel MJ,Grilló MJ,Marín CM,Barberán M,Blasco JM

    更新日期：2008-05-19 00:00:00

  • Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study.

    abstract：:The bioavailability of oseltamivir phosphate and oseltamivir carboxylate were assessed in healthy volunteers when delivered as a solution of the active pharmaceutical ingredient (API) compared with the commercial capsule formulation. The 90% confidence intervals (CIs) for the ratios of the two treatments (capsule vers...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2006.05.080

    authors： Brewster M,Smith JR,Dutkowski R,Robson R

    更新日期：2006-11-10 00:00:00

  • Consecutive CT in vivo lung imaging as quantitative parameter of influenza vaccine efficacy in the ferret model.

    abstract：:Preclinical vaccine efficacy studies are generally limited to certain read out parameters such as assessment of virus titers in swabs and organs, clinical signs, serum antibody titers, and pathological changes. These parameters are not always routinely applied and not always scheduled in a logical standardized way. We...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.10.008

    authors： Veldhuis Kroeze EJ,Stittelaar KJ,Teeuwsen VJ,Dijkshoorn ML,van Amerongen G,de Waal L,Kuiken T,Krestin GP,Hinkula J,Osterhaus AD

    更新日期：2012-12-07 00:00:00

  • A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.

    abstract：:We tested a candidate live, oral, rotavirus vaccine (Rotavin-M1™) derived from an attenuated G1P [8] strain (KH0118-2003) isolated from a child in Vietnam. The vaccine was tested first for safety in 29 healthy adults. When deemed safe, it was further tested for safety and immunogenicity in 160 infants (4 groups) aged ...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2011.07.118

    authors： Dang DA,Nguyen VT,Vu DT,Nguyen TH,Nguyen DM,Yuhuan W,Baoming J,Nguyen DH,Le TL,Rotavin-M1 Vaccine Trial Group.

    更新日期：2012-04-27 00:00:00

  • Interventions to reduce the burden of vaccine-preventable diseases among migrants and refugees worldwide: A scoping review of published literature, 2006-2018.

    abstract：BACKGROUND:Disparities in vaccine-preventable disease (VPD) burden and immunisation coverage between migrants and refugees and their host populations have been described in numerous countries worldwide. Effective strategies are required to reduce the health disparities and immunisation inequities experienced by migrant...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2020.09.054

    authors： Charania NA,Gaze N,Kung JY,Brooks S

    更新日期：2020-10-27 00:00:00

  • A population-based reminder intervention to improve human papillomavirus vaccination rates among adolescents at routine vaccination age.

    abstract：OBJECTIVES:Public health authorities have the resources to conduct efficient immunization reminder interventions to improve vaccine uptake. The objective of this initiative was to design and implement a cost-effective centralized HPV vaccine reminder using New York State Immunization Information System data as one of f...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.06.056

    authors： Coley S,Hoefer D,Rausch-Phung E

    更新日期：2018-08-06 00:00:00

  • Chicken HSP70 DNA vaccine inhibits tumor growth in a canine cancer model.

    abstract：:Immunization with xenogeneic DNA is a promising cancer treatment to overcome tolerance to self-antigens. Heat shock protein 70 (HSP70) is over-expressed in various kinds of tumors and is believed to be involved in tumor progression. This study tested a xenogeneic chicken HSP70 (chHSP70) DNA vaccine in an experimental ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.02.031

    authors： Yu WY,Chuang TF,Guichard C,El-Garch H,Tierny D,Laio AT,Lin CS,Chiou KH,Tsai CL,Liu CH,Li WC,Fischer L,Chu RM

    更新日期：2011-04-18 00:00:00

  • A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.

    abstract：BACKGROUND:FP-01.1 is a novel synthetic influenza A vaccine consisting of six fluorocarbon-modified 35-mer peptides that encapsulate multiple CD4+ and CD8+ T-cell epitopes and is designed to induce an immune response across a broad population. METHODS:FP-01.1 was evaluated for safety and immunogenicity in a randomised...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2014.06.006

    authors： Francis JN,Bunce CJ,Horlock C,Watson JM,Warrington SJ,Georges B,Brown CB

    更新日期：2015-01-03 00:00:00